Evidence map›Paper›PMID 40022429›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2025

Time-Sensitive Antibiotic Adjustments in Gram-Negative Bacteremia: A Survival Perspective.

Yunwei Zheng, Chuwen Zhao, Bo Liao, Fuxing Li, Yaping Hang, Junqi Zhu, Youling Fang, Yanhua Liu, Longhua Hu

Abstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunwei ZhengJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Chuwen ZhaoJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Bo LiaoFirst Clinical Medical School of Nanchang University, Nanchang, Jiangxi, China.
Fuxing LiJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Yaping HangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Junqi ZhuJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Youling FangJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Yanhua LiuJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Longhua HuJiangxi Province Key Laboratory of Immunology and Inflammation, Jiangxi Provincial Clinical Research Center for Laboratory Medicine, Department of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND This retrospective study was designed to assess risk factors for increased 30-day mortality from bacteremia caused by Escherichia coli or Klebsiella pneumoniae and to calculate the optimal point of time for patients to move from inappropriate empirical antimicrobial therapy to appropriate treatment. MATERIAL AND METHODS This retrospective study analyzed data from 610 patients with a diagnosis of E. coli- and K. pneumoniae-induced bacteremia collected between 2020 and 2023, including population-based information, infection bacteria, comorbidities, and treatment duration. Patients were categorized into 2 groups based on whether they received appropriate empirical antibiotic therapy (AEAT) or inappropriate empirical antibiotic therapy (IEAT). Propensity score-matched (PSM) analysis was performed using 1: 1 nearest neighbor matching. Receiver operating characteristic (ROC) curve analysis determined the time point for patients in the IEAT group to transition to appropriate therapy. RESULTS The study found that 30-day mortality was higher in the IEAT group than in the AEAT group (P=0.043). Multifactorial Cox regression analysis after PSM indicated that Pitt score (P<0.001), age-adjusted Charlson comorbidity index score (P<0.001), and inappropriate treatment days (P=0.018) were independent risk factors for increased 30-day mortality. The area under the ROC curve value was 0.613, and the maximum Youden index corresponded to a time turning point of 8 days. CONCLUSIONS Pitt and aCCI scores and inappropriate treatment days are significant risk factors for increased 30-day mortality in patients with E. coli or K. pneumoniae. Timely transition from inappropriate antibiotic to appropriate antibiotic therapy within 8 days was found to improve survival.

Indexed as

Anti-Bacterial AgentsBacteremiaAgedAged, 80 and overEscherichia coliFemaleHumansKlebsiella InfectionsKlebsiella pneumoniaeMaleMiddle AgedPropensity ScoreRetrospective StudiesRisk FactorsROC CurveTime FactorsAnti-Bacterial Agents

Identifiers

PMID40022429
PMCPMC11881518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.